Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLPAD8)

• Drug Name: S,S-(2-Hydroxyethyl)Thiocysteine Drug Info
• Synonyms: AC1OAH3S

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 170018
  ChEBI ID: CHEBI:74104
  CAS Number: CAS 38254-63-6
  TTD Drug ID: DMLPAD8

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 4B (PDE4B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DENBUFYLLINE	DM2R15Q	Cognitive impairment	6D71	Phase 3	[2]
SOTB07	DMIG4OX	Asthma	CA23	Phase 3	[3]
BI 1015550	DM6DO2P	Idiopathic pulmonary fibrosis	CB03.4	Phase 3	[4]
AN-2898	DMDK7CL	Atopic dermatitis	EA80	Phase 2	[5]
GPD-1116	DMOQ7YI	Asthma	CA23	Phase 2	[6]
TA-7906	DMZTAJL	Atopic dermatitis	EA80	Phase 2	[7]
HT-0712	DM2WP8F	Cognitive impairment	6D71	Phase 2	[3]
TOFIMILAST	DMLCUAS	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
AWD-12-281	DMVADGZ	Rhinitis	FA20	Phase 2	[9]
LIRIMILAST	DMD4KAU	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]

Drug(s) Targeting Delta-aminolevulinic acid dehydratase (ALAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminolevulinic acid hci	DMS4BLQ	Acne vulgaris	ED80	Approved	[10]
Porphobilinogen	DM5HMTB	N. A.	N. A.	Phase 2	[1]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[1]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
Delta-Amino Valeric Acid	DMV7IAK	Discovery agent	N.A.	Investigative	[1]
4,7-Dioxosebacic Acid	DML5302	Discovery agent	N.A.	Investigative	[1]
Laevulinic Acid	DMTZ17V	Discovery agent	N.A.	Investigative	[1]
3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid	DMQXPM3	Discovery agent	N.A.	Investigative	[1]
5-Fluorolevulinic Acid	DMDV48S	Discovery agent	N.A.	Investigative	[1]
4-Oxosebacic Acid	DMADSUY	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Candida Thymidylate synthase (Candi TMP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[11]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[12]
Pemetrexed	DMMX2E6	Central nervous system lymphoma	2B33.5	Approved	[13]
Trifluridine	DMG2YBD	Herpetic keratitis	1F00.10	Approved	[14]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[15]
Raltitrexed	DMT9K8G	Rectal adenocarcinoma	2B92	Approved	[16]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[17]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[18]
Nolatrexed	DMOF0CA	Solid tumour/cancer	2A00-2F9Z	Phase 3	[19]
Plevitrexed (R)-isomer	DMTL39C	Gastric adenocarcinoma	2B72	Phase 2	[20]

Drug(s) Targeting Phosphodiesterase 1 (PDE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vinpocetine	DMVN2E6	Ischemic stroke	8B11.5Z	Approved	[21]
ITI-214	DM08TH3	Parkinson disease	8A00.0	Phase 1/2	[22]
ZAPRINAST	DMGH3T5	N. A.	N. A.	Terminated	[23]
BIBW-22	DMXIH3Q	Solid tumour/cancer	2A00-2F9Z	Terminated	[24]
isobutylmethylxanthine	DM46F5X	Discovery agent	N.A.	Investigative	[25]
BUFROLIN	DM61F5W	Discovery agent	N.A.	Investigative	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[1]
Delta-aminolevulinic acid dehydratase (ALAD)	TTJHKYD	HEM2_HUMAN	Inhibitor	[1]
Maspin (SERPINB5)	TT1KW50	SPB5_HUMAN	Inhibitor	[1]
Mycobacterium DTDP-dehydrorhamnose epimerase rmlC (MycB rmlC)	TTKGY3F	RMLC_MYCTU	Inhibitor	[1]
Phosphodiesterase 1 (PDE1)	TTHQENC	NOUNIPROTAC	Inhibitor	[1]
Phosphodiesterase 4B (PDE4B)	TTVIAT9	PDE4B_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301).
• [4] BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. 2022 Apr 20;13:838449.
• [5] An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46.
• [6] Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204.
• [7] Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6.
• [8] Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
• [9] The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17.
• [10] Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9.
• [11] The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
• [12] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [13] Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
• [14] Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
• [15] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
• [16] DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
• [17] Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
• [18] Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
• [19] A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
• [20] Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
• [21] Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
• [24] BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
• [25] A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.